[1] Chinese Pharmacopoeia Commission.The Pharmacopoeia of the People's Republic of China notes for clinical use of traditional Chinese medicine preparation volume, the 2015 edition(中华人民共和国药典临床用药须知中药成方制剂卷2015年版)[M]. Beijing: China Medical Science and Technology Press, 2015, 336-337. [2] ZHONG ZY, ZHENG JL, ZHONG HC, et al.Pharmacodynamics of Keke tablets[J]. Chinese Traditional Patent Medicine(中成药), 2013, 35(8): 1609-1614. [3] LIN L, WANG Q, LI SY, et al.Keke tablets in the treatment of chronic bronchitis: a multicenter randomized controlled clinical trial[J].China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2015, 30(7): 2636-2638. [4] LIN L, WANG Q, LI SY, et al.Multiple-center, randomized, double-blinded controlled trial of Keke tablets for treatment of acute tracheobronchitis[J]. Journal of Guangzhou University of Traditional Chinese Medicine(广州中医药大学学报), 2014, 31(3): 341-342. [5] ZHONG LM.MAHs'principal responsibilities for safety risk during the whole-life cycle of drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(11): 666-669. [6] WANG CZ, CHEN XB, LIU XM, et al.ADR monitoring in pharmaceutical manufacturers under the background of marketing authorization holder system[J].Anhui Medical and Pharmaceutical Journal(安徽医药), 2020, 24(5): 1056-1060. [7] CAO JY, SHU CZ, WEN XP.Analysis of the usage of Chinese patent medicine[J]. Chin J of Clinical Rational Drug Use(临床合理用药),2020, 13(1): 169-171. [8] Chinese Pharmacopoeia Commission.The Pharmacopoeia of the People's Republic of China notes for Clinical Use Of Traditional Chinese Medicine Decoction Pieces Volume, the 2015 edition(中华人民共和国药典临床用药须知中药成方制剂卷2015年版)[M]. Beijing: China Medical Science and Technology Press, 2015: 74-78. [9] ZHANG ZB.A case of ephedrine caused a sharp increase in blood pressure[J]. Sichuan Medical Journal(四川医药),2001, 22(12): 1107. [10] ZHAN ZL.A case of severe hypertension induced by ephedrine in Parkinson's disease[J]. Inner Mongolia Med J(内蒙古医学杂志),2010, 42(4): 492. [11] PAN GH, SUN XR.The safety evaluation of ephedra and its preparation aboard[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2007, 4(2): 111-117. [12] ZHANG CY, CHENG RZ, WANG T.Research status of pharmaco-dynamic substance basis and safety of ephedra[J]. Hubei Journal of TCM(湖北中医杂志), 2018, 40(2): 58-61. [13] ZHAO TT, ZHAO JZ.Considerations of standardize domestic approved drug package inserts[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2020, 36(14): 2153-2155. [14] WANG Y, ZOU Z, LI F.Analysis of 159 ADR reports induced by Chinese patent medicine[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2019, 23(11): 2320-2323. [15] WU SF, JIN Y, CHANG H, et al.Drug risk communication in the European Union and United States between regulators and the public[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 87-92. [16] HOU HJ, WANG L, LI XM.Current situation, existing problems and countermeasures of drug package inserts of Chinese traditional patent medicine[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2020(2): 32-39. |